Commentary · 28 Feb 2026
Conference abstractPublished 13 Aug 2013
Pharmacometabolomics and individualized treatment strategy: High serum glutamate level is associated with positive response to acamprosate treatment
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
A camprosate is approved for treatment of alcohol dependence and is known to stabilize a glutamatergic imbalance in the brain. However, the efficacy of acamprosate is not universal in all patients. We identified potential predictors of acamprosate response using a pharmacometabolomics approach and revealed a mechanism for acamprosate action. To identify the blood metabolite markers of acamprosate response, 40 amino acid metabolites were screened using UPLC-MS/MS. We observed that glutamate levels were significantly higher at baseline in the 51 responders compared to the 39 non-responders [p = 0.007]. In addition, after adjustment for baseline PACS, increased glutamate was significantly associated with increased probability of a favorable acamprosate response (OR=1.047, p=0.010). This indicates that an escalated baseline glutamate level itself in the acamprosate responder group provides essential information regarding likelihood of a positive treatment outcome beyond clinical measures. We also identified glutamate-ammonia condensation by glutamine synthetase (GS) as an important pathway for acamprosate action in the acamprosate responder group. Consistent with glutamate, ammonia also showed a significant profile change at baseline and after acamprosate treatment in the responder group. To confirm whether acamprosate promotes GS metabolism, we measured serum glutamate levels after acamprosate treatment in mice. Interestingly, acute acamprosate treatment reduced serum glutamate levels for a period of time longer than its steady state in blood (30min), indicating a strong glutamate metabolism alteration in the serum by acamprosate treatment. Overall, these findings suggest that high baseline glutamate levels may be a biomarker to predict the efficacy of acamprosate treatment and glutamate regulation by GS metabolism may play an important role in pharmacological intervention of acamprosate in maintaining abstinence. Since GS is highly expressed in astrocytes, these data provide a possible mechanism underlying the pharmacological efficacy of acamprosate in stabilizing a hyper-glutamatergic state in the brain
Subjects
Mental Health and PsychologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Addiction Research & Therapy.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Addiction Research & Therapy
- SubjectMental Health and Psychology
- BylineArticles whose byline prints “Doo-Sup Choi”